Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Date:4/24/2012

4.05 is unchanged from our previous outlook. 
  • At current rates, foreign currency rate changes are expected to reduce otherwise reportable diluted EPS by approximately $0.10 which is included in the outlook.  This outlook also includes approximately $0.10 per diluted share of higher income tax expense resulting from a higher effective tax rate of 30 - 31% compared to 29% in 2011.  A $0.05 - $0.07 per share benefit from the acquisitions of BioReliance and Research Organics is included in this outlook.  See 2012 Outlook below.
  • Net cash provided by operating activities and free cash flow are expected to be approximately $550 million and $425 million, respectively for 2012, each a $25 million increase from our prior outlook.
  • CEO's STATEMENT:  Commenting on first quarter 2012 performance, President and CEO Rakesh Sachdev said, "We are pleased with our reported sales of $665 million and diluted adjusted EPS of $0.99 which are the best quarterly results in our history.  The 4% organic growth in our Research business was slightly higher than our expectation, even as uncertainties in the global economic environment and in pharma and academic research funding in the U.S. and Europe continued.  SAFC had its strongest quarter ever with sales of $197 million.  As expected, the organic sales growth rate for SAFC in the first quarter was in the low single digits due to the pre-buy in the SAFC Bioscience business in early 2011, temporary weakness in the LED markets and production capacity constraints in Hitech.  We continue to expect sales growth in SAFC to move from low to mid single digits in the first half of the year to low double digits for the second half. 

    Following the acquisition of BioReliance in January 2012, we continued to pursue our M&A strategy to add bolt-on businesses with the recently announced acquisition of Research Organics, a leading supplier o
    '/>"/>

    SOURCE Sigma-Aldrich
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. CRF Institute Names Sigma-Aldrich Top Employer Europe 2012
    2. Sigma-Aldrich Enhances Asia-Pacific Customer Support With New Distribution and Packaging Capabilities in India
    3. Sigma-Aldrich Corporation Will Hold Its Business Review March 29, 2012
    4. Sigma-Aldrich (Nasdaq:SIAL) Declares Increased Quarterly Dividend
    5. Sigma-Aldrich Completes Acquisition of BioReliance
    6. Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
    7. Sigma-Aldrich Corporation to Present at Upcoming Investor Conference
    8. Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.
    9. Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences
    10. Sigma-Aldrich (NASDAQ:SIAL) Declares Quarterly Dividend
    11. Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
    (Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
    (Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
    Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
    ... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
    ... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
    Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
    (Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... and other minor infections might trigger a strong but brief ... study suggests. Just five out of 100,000 children a ... Heather Fullerton, lead author of the study and a professor ... Francisco Benioff Children,s Hospital. "It seems infections play a role ...
    (Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... reconstruction after a mastectomy has long been an option, but ... women choose it. "The most common reasons women didn,t ... weren,t interested in more surgery or they were focused on ... of breast surgery at Memorial Sloan Kettering Cancer Center, in ...
    (Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... of Pittsburgh School of Medicine. , Their findings, published ... acute hemodialysis, an aggressive method that is standardly used ... a definitive benefit to the patient. , "Our findings ...
    (Date:8/20/2014)... approach to treating cancer - using Botox. A study ... Translational Medicine shows that cancer growth could be ... are linked to cancer stem cells. The approach thus ... treatment cheap, safe and efficient. The researchers have thus ... start testing on humans. , The nervous system is ...
    (Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... waste products from the blood did not improve survival ... an analysis led by experts at the University ... findings, published online today in the journal PLOS ... is standardly used for people with sudden kidney failure, ...
    Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
    ... Pakistan Tuesday enhanced their cooperation in the crucial area ... polio and avian flu. // ,"The ... exchanged ideas on management of avian influenza," external affairs ... the first meeting of the India-Pakistan Joint Commission technical-level ...
    ... over reports of malarial deaths in Jharkhand's Sahibganj district, the ... // , today urged the health department to step up ... at the earliest direct its medical teams to find out ... disease has afflicted several people in the district, JD(U) spokesman ...
    ... A recent study has revealed that the place of birth determines ... far lower life expectancy than those born in south east England ... city was found to be 69.3 it was found to be ... conducted the research and it has ranked the 10 best and ...
    ... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
    ... Boards (DHBs), striking junior doctors returned to hospital calling off their ... doctor's union - Resident Doctors' Association (RDA) and the DHBs met ... planned to meet on Thursday for confirming the results. ... lasted for 5 days. , ,But unfortunately last time ...
    ... Carolina have found that very few of the patients ... resulted due to chronic obstructive pulmonary disease (COPD) such ... and management. ,Explaining that ideal care means ... the treatment guidelines for this condition and none of ...
    Cached Medicine News:Health News:Life Expectancy Determined by Place of Birth 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: